Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy
Author:
- 6 December 2024
- journal article
- review article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2024 (1) , 200-205
Abstract
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy typically characterized by anemia, thrombocytopenia, and end-organ injury. aHUS occurs due to endothelial injury resulting from overactivation of the alternative pathway of the complement system. The etiology of the dysregulated complement system is either a genetic mutation in 1 or more complement proteins or an acquired deficiency due to autoantibodies. Over the past decade, advancements in our understanding of the role of complement in the pathophysiology of aHUS as well as the availability of anticomplement drugs has been a game-changer for our patients. These drugs have revolutionized the clinical course, outcome, and prognosis of this disease. Therefore, all patients in whom aHUS is suspected should undergo testing for complement genetic variants and autoantibodies. In approximately 30% to 40% of patients, a genetic variant of uncertain significance (VUS) may be identified. Such patients should undergo further testing to define the significance of the VUS. A combination of antigenic, functional, and biomarker analyses can assist in establishing the significance of the variants and thereby define the etiology in most patients. These analyses will also help to determine the duration of treatment based on the individual's genetic alteration. This review aims to shed light on the diagnosis and management of aHUS and discusses how to stratify patients to determine who can safely discontinue anticomplement therapy.Keywords
This publication has 40 references indexed in Scilit:
- Complement inhibitors in pediatric kidney diseases: new therapeutic opportunitiesPediatric Nephrology, 2023
- Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic SyndromeKidney International Reports, 2023
- Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS StudyKidney International Reports, 2022
- Systematic review of atypical hemolytic uremic syndrome biomarkersPediatric Nephrology, 2022
- Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in AdultsKidney International Reports, 2021
- A Multimodality Approach to Assessing Factor I Genetic Variants in Atypical Hemolytic Uremic SyndromeKidney International Reports, 2019
- Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)—a question to be addressed in a scientific wayPediatric Nephrology, 2019
- Extra-renal manifestations of atypical hemolytic uremic syndromePediatric Nephrology, 2018
- Complete functional characterization of disease-associated genetic variants in the complement factor H geneKidney International, 2018
- Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies ConferenceKidney International, 2017